Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Proof-of-concept Phase 2a, Double-blind, 2-arm Trial to Investigate the Efficacy and Safety of Twice Daily Delgocitinib Cream 20 mg/g Compared With Cream Vehicle During a 16-week Treatment Period in Adult Subjects With Mild to Severe Palmoplantar Pustulosis

NCT07013201 is registered in ClinicalTrials.gov with LEO Pharma as lead sponsor.

NCT NCT07013201
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07013201 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Proof-of-concept Phase 2a, Double-blind, 2-arm Trial to Investigate the Efficacy and Safety of Twice Daily Delgocitinib Cream 20 mg/g Compared With Cream Vehicle During a 16-week Treatment Period in Adult Subjects With Mild to Severe Palmoplantar Pustulosis
Lead sponsor
LEO Pharma
Phase
Phase 2
Overall status
Recruiting
Start date
September 11, 2025
Completion date
December 14, 2026
Enrollment
135 (estimated)
Sites
40

Conditions

As the registry lists them; a condition with its own page is linked.

palmoplantar pustulosis